JP2010533498A5 - - Google Patents

Download PDF

Info

Publication number
JP2010533498A5
JP2010533498A5 JP2010517161A JP2010517161A JP2010533498A5 JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5 JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010517161 A JP2010517161 A JP 2010517161A JP 2010533498 A5 JP2010533498 A5 JP 2010533498A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010517161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533498A (ja
JP5868593B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/070344 external-priority patent/WO2009012394A1/en
Publication of JP2010533498A publication Critical patent/JP2010533498A/ja
Publication of JP2010533498A5 publication Critical patent/JP2010533498A5/ja
Application granted granted Critical
Publication of JP5868593B2 publication Critical patent/JP5868593B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010517161A 2007-07-17 2008-07-17 Glypican−3に対するモノクローナル抗体 Expired - Fee Related JP5868593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95984507P 2007-07-17 2007-07-17
US60/959,845 2007-07-17
PCT/US2008/070344 WO2009012394A1 (en) 2007-07-17 2008-07-17 Monoclonal antibodies against glypican-3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014137921A Division JP2014236734A (ja) 2007-07-17 2014-07-03 Glypican−3に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2010533498A JP2010533498A (ja) 2010-10-28
JP2010533498A5 true JP2010533498A5 (cg-RX-API-DMAC7.html) 2011-07-21
JP5868593B2 JP5868593B2 (ja) 2016-02-24

Family

ID=39874207

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010517161A Expired - Fee Related JP5868593B2 (ja) 2007-07-17 2008-07-17 Glypican−3に対するモノクローナル抗体
JP2014137921A Pending JP2014236734A (ja) 2007-07-17 2014-07-03 Glypican−3に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014137921A Pending JP2014236734A (ja) 2007-07-17 2014-07-03 Glypican−3に対するモノクローナル抗体

Country Status (18)

Country Link
US (2) US8680247B2 (cg-RX-API-DMAC7.html)
EP (1) EP2178921B1 (cg-RX-API-DMAC7.html)
JP (2) JP5868593B2 (cg-RX-API-DMAC7.html)
KR (2) KR101527342B1 (cg-RX-API-DMAC7.html)
CN (1) CN101815726B (cg-RX-API-DMAC7.html)
AU (1) AU2008275985B2 (cg-RX-API-DMAC7.html)
CY (1) CY1117236T1 (cg-RX-API-DMAC7.html)
DK (1) DK2178921T3 (cg-RX-API-DMAC7.html)
ES (1) ES2562790T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160270T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028737T2 (cg-RX-API-DMAC7.html)
ME (1) ME02345B (cg-RX-API-DMAC7.html)
MX (1) MX2010000537A (cg-RX-API-DMAC7.html)
PL (1) PL2178921T3 (cg-RX-API-DMAC7.html)
PT (1) PT2178921E (cg-RX-API-DMAC7.html)
RS (1) RS54624B1 (cg-RX-API-DMAC7.html)
SI (1) SI2178921T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009012394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2009012394A1 (en) * 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
MY148637A (en) * 2007-09-28 2013-05-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CA2760246A1 (en) * 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
MX345399B (es) * 2010-12-28 2017-01-30 Chugai Pharmaceutical Co Ltd Metodo de cultivo de celulas animales.
CN105968209B (zh) 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140322216A1 (en) * 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
BR112015019432A2 (pt) 2013-02-14 2017-08-22 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e uso
EA201690388A1 (ru) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016081746A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
AU2016206798A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
KR20180008649A (ko) 2015-05-18 2018-01-24 피어이스 파마슈티컬즈 게엠베하 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인
US11370845B2 (en) * 2015-06-24 2022-06-28 Keio University Anti-glypican-1-immunizing antigen receptor
DK3333192T3 (da) * 2015-08-03 2021-05-31 Cafa Therapeutics Ltd Antistof imod glypican-3 og anvendelse deraf
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
JP2019505575A (ja) 2015-12-21 2019-02-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 部位特異的な結合のための変異型抗体
CN105717303A (zh) * 2016-01-29 2016-06-29 山东康力医疗器械科技有限公司 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN106084041A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种全人源抗GPC3的全分子IgG抗体及其应用
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
SG11201909728XA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
EP3630833A1 (en) 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技(上海)有限公司 抗gpc-3抗体及其用途
EA202092747A1 (ru) 2018-05-29 2021-03-16 Бристол-Маерс Сквибб Компани Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
FI3886914T3 (fi) 2018-11-30 2023-05-26 Bristol Myers Squibb Co Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä
KR20210102334A (ko) 2018-12-12 2021-08-19 브리스톨-마이어스 스큅 컴퍼니 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
CN120118189A (zh) * 2019-03-21 2025-06-10 新加坡科技研究局 针对磷脂酰肌醇蛋白聚糖-3的人单克隆抗体
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
KR20230007452A (ko) * 2020-05-07 2023-01-12 페인스 테라퓨틱스 인코포레이티드 항종양 관련 항원 항체 및 이의 용도
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
KR20240000479A (ko) * 2021-04-23 2024-01-02 상하이 헨리우스 바이오테크, 인크. 항gpc3 항체 및 사용 방법
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
KR20240112375A (ko) * 2021-08-19 2024-07-18 아디셋 테라퓨틱스, 인크. 막 결합된 글리피칸-3의 검출 방법
CN118994403B (zh) * 2021-10-15 2025-04-01 乐普创一生物科技(上海)有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 公司 药物接头及其抗体缀合物
TW202432596A (zh) * 2022-11-01 2024-08-16 大陸商上海齊魯製藥研究中心有限公司 針對磷脂醯肌醇蛋白聚醣3的雙特異性抗體及其應用
AU2024305352A1 (en) 2023-06-12 2025-12-04 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426001B2 (ja) 1993-09-16 2003-07-14 東芝機械株式会社 ステージ内蔵型雰囲気室装置
ATE390933T1 (de) * 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
DK2208784T3 (da) 2001-06-22 2013-03-18 Chugai Pharmaceutical Co Ltd Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
WO2004067571A1 (fr) 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
JP4501859B2 (ja) 2003-06-27 2010-07-14 日本電気株式会社 薄膜トランジスタ、薄膜トランジスタ基板、電子機器及び多結晶半導体薄膜の製造方法
CN102702353A (zh) * 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
SI1800693T1 (sl) 2004-08-24 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Adjuvantna terapija z uporabo protitelesa proti glipikanu 3
RU2451030C2 (ru) 2004-10-26 2012-05-20 Чугаи Сейяку Кабусики Кайся Анти-глипикан 3-антитело, имеющее модифицированную сахарную цепь
US7988971B2 (en) * 2005-03-14 2011-08-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
CN104356236B (zh) * 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7744800B2 (en) 2006-01-06 2010-06-29 Molded Fiber Glass Companies Method and apparatus for controlling the stacking height of stackable products during compression molding off stops
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
WO2009012394A1 (en) * 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use

Similar Documents

Publication Publication Date Title
JP2010533498A5 (cg-RX-API-DMAC7.html)
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP2014518615A5 (cg-RX-API-DMAC7.html)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
HRP20191483T1 (hr) Protutijela koja reagiraju s b7-h3, njihovi imunološki aktivni fragmenti i njihova upotreba
JP2012523848A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2013545455A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2014039548A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2020525032A5 (cg-RX-API-DMAC7.html)
JP2013519364A5 (cg-RX-API-DMAC7.html)
JP2011526480A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2018502060A5 (cg-RX-API-DMAC7.html)
JP2010502183A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
JP2013545738A5 (cg-RX-API-DMAC7.html)
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2010526028A5 (cg-RX-API-DMAC7.html)
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2013544756A5 (cg-RX-API-DMAC7.html)
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение